[Growth in @entity1 with XXXX ].

@entity1 @entity2338 @entity17690 @entity918 @entity5422 @entity4683 @entity976 @entity3040 @entity4337 @entity2010
Commercial preparations of vasopressin for the treatment of @entity2010 are not available in Mexico. Besides, the hormone is useless in the @entity3040 variety. In the department of Endocrinology at the Hospital Infantil de Mexico, a preparation containing @entity918 , @entity17690 and @entity4337 , which reduces urinary volumes in about two thirds, is employed in all varieties of the disease. Growth in stature was investigated in 44 @entity1 under treatment, attending the Endocrine Outpatient Clinic since 1967 for a period of 2 to 12 years. Clinical material included 29 males and 15 females. There were 23 idiopathic, 7 histiocytosis, 5 @entity3040 , 4 @entity976 , 2 psychogenic @entity4683 , 2 traumatic and 1, as a sequel of tuberculous @entity5422 . Six idiopathic, 2 @entity3040 , 2 traumatic, 1 histiocytosis, and 1 psychogenic proceeded between percentiles 3 and 97, parallel to the nearest line of reference along the whole period of study. Two @entity3040 , 2 histiocytosis, 1 psychogenic, 1 post- @entity5422 and 14 idiopathic, grew below the third percentile, but parallel to it. One @entity3040 , 4 histiocytosis, 4 @entity976 and 3 idiopathic progressively departed from the initial centile. Two of the latter had @entity2338 , and 1 had been very irregularly treated. It is concluded that the therapy employed limits stature impairment but does not produce catch-up growth. Accordingly, it is proposed that the treatment of @entity2010 should be started as early as possible, and that if progress in stature is appreciably deteriorated, the presence of additional pathology should be suspected.
